-
@pfizer#BIO2018 @AVIVA1950 @Pharma_BI in Cambridge study sensors on patients contact dermatitis patients sensors monitor movement#AI text mining sensation reported by patients with sensors#disease trajectory monitored drug device external partnership
-
@Pfizer#BIO2018 @AVIVA1950 @Pharma_BI#amyloid#cardiomyopathy new drug: Biotech in Scripps, CA and another in Cambridge, MA and @Pfizer as Pharma collaboration with biotech Partnership with UPenn with Duke, NC agility in small co scale in Pharma
-
@Pfizer#BIO2018 @AVIVA1950 @Pharma_BI#FDA and Medical community decide on directions for surrogate followed by survival NASH redefine NEW#endpoints drug innovations will move faster Vaccine for NASH growing obesity population Network for collaboration
-
@pfizer immunicity correlated#vaccines confirm benefit in#registry based study#industry#consortium patient to benefit early on while cost benefit be known later inflammatory indicators across diseases JAKS inhibitors which drug for which patient#molecularbiology
-
@Pfizer#BIO2018 @AVIVA1950 @Pharma_BI redefine#medicine by genomics clinical trials on patients with Gene expression 150 patients 60% improve rate new drug approved in 2011 in oncology how sustain innovation by cost effective trials? Patient selection
-
@pfizer#CEO Mikael Dolsten#BIO2018 @AVIVA1950@pharma_BI R&D budget for#neuroscience#oncology#venture contribution capital allocation focus on deep expertise in#translational multiple drugs in multiple indications Lipitor dependence ends patent expiration
-
#BIO2018@Pharma_BI@AVIVA1950#CS#Genomics only by knowing both one can develop applications in#Medicine#tools#analytics vs#AI#killer questions are the hard part vs#tools#domain expertise needed for structural models type of data collected#AI may not be best@atulbutte
-
#BIO2018@Pharma_BI@AVIVA1950@atulbutte#PrecisionMedicine#drugdiscovery for idiopathic fibrosis using#AI CONNECTION OF DRUG AND DISEASE known after development, pharma needs that BEFORE a drug is developed, clinics based on BRCA for treatment, finding binding targets/drug
-
#PrecisionMedicine for patients goals apply right approach to care right drug#BIO2018@Pharma_BI@AVIVA1950 respond to therapy is a HC goal combined with patient goals
-
#BIO2018@Pharma_BI@AVIVA1950 @FoundationMedicine in 7 days genomic data, clinical data and patient#characterization of patient took place#AI in#imaging#longitudinal#ML clean data sets are a must#algorithm for patient total clinical profile
-
#BIO2018@Pharma_BI@AVIVA1950#SELECT COHORT is assisted by#AI for clinical trials of rare types of cancers on small population of patients. Synthetic data compared with observed data for#validation#sharing#data can get wrong results by using#shared#data
-
#BIO2018@pharma_BI@AVIVA1950#EMR @FoundationMedicine sequenced 200,000 Cancer patients genome use data to Target positive predicted responders to accelerate clinical trials.@Regeneron use of#AI on genomic data for#patienttargeting
-
#BIO2018#pharma_BI@AVIVA1950@streamline#Bcorp#patients-based#social value#time in leadership is brief#move the dime#conviction
-
#BIO2018#pharma_BI #@AVIVA1950#LifeSciences#Industry#Leader to launch an industry#scienceleaders#taxincentives#legislation stick initiative#job#growth#strategy#metrowest
-
#DigitalHealth Breakthrough#BusinessModels, June 5, 2018@BIOConvention, Boston, BCEC#BIO2018#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 https://pharmaceuticalintelligence.com/2018/06/05/digital-health-breakthrough-business-models-june-5-2018-bioconvention-boston-bcec/ … via@Pharma_BI -
#Biotechnology#Financing#Deal-Making and#State of the#Industry: Findings from@EY#IndustryAnalysis, June 5, 1:45-2:45PM, BIO 2018!, Boston, BCEC https://pharmaceuticalintelligence.com/2018/06/05/biotechnology-financing-deal-making-and-state-of-the-industry-findings-from-ey-industry-analysis-june-5-145-245pm-bio-2018-boston-bcec/ … via@Pharma_BI -
@KatrineBosley
#CEO @EditasMedicine Valuation for 23andme? Each pool of capital has different investors been attracted#BIO2018#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 -
@JohnMaraganore
#CEO @ALNYLAMPHARMACEUTICALS In 16 years rained $4Billion and expenses $2.5Billion – still not profitable – that what it takes#BIO2018#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 -
@JeanFrancisFormela
@AtlasVenture Science is extraordinary A lot of capital and very many tech ventures over supply of capital accelerates the business More capital is better, what to invest is critical#BIO2018#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 -
US is not the only player, CANADA’ universal payer system made major strides lung cancer experienced development of 50 drug base on tumor type predict likelihood drug resistance BR CA patient which not require therapy
@PMC#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 -
@RajuKucherlapati Integration of EMR Partners leader missing link is integration of Genomic dat aat the patient level with clinical dat of patients Patients will manage their 23andme data PM is global vs access to care
@PMC#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 -
@RajuKucherlapati
#Database with million of people with genetic and medical information — searches of profile too group patients for optimal#drugmatching#integration of#EMR with DB of#genetics – IBM@PMC#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 -
@RajuKucherlapati
@PMC@HMS Detection at pre-natal stages of multiple fetal disorders, abnormality, diagnosis drive treatment – genetic testing critical in cost Cardiomayopaty: in Young athlete genetic disorder#BIO2018#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 -
Sajeev Kohli (11th Grade, Waterloo, On, Canada)Receives Top Honor at International BioGENEius Challenge Students from California, Washington and Germany named runners-up June 5, 2018 – Boston, Massachusetts –
#BIO2018#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 -
#PressConference:#Exosome based#DrugDelivery Systems, June 5, BIO 2018!, Boston, BCEC#BIO2018#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 https://pharmaceuticalintelligence.com/2018/06/05/press-conference-exosome-based-drug-delivery-systems-june-5-bio-2018-boston-bcec/ … via@Pharma_BI -
Tales from the
#TranslationalFrontier – Four Unique Approaches to Turning#NovelBiology into#InvestableInnovations@BIOConvention#BIO2018 https://pharmaceuticalintelligence.com/2018/06/04/tales-from-the-translational-frontier-four-unique-approaches-to-turning-novel-biology-into-investable-innovations-bioconvention-bio2018/ … via@Pharma_BI -
#FiresideChat with@JamesBradner, MD, President, Novartis Institutes for Biomedical Research (NIBR)@BIO2018! https://pharmaceuticalintelligence.com/2018/06/04/fireside-chat-with-james-jay-bradner-md-president-novartis-institutes-for-biomedical-research-nibr-bio2018/ … via@Pharma_BI -
June 4, 2018 –
@DoD#MedicalInnovation and#BiodefenseForum, BIO 2018! at Boston BCEC@DoD#MedicalInnovation#BiodefenseForum#BIO2018#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 https://pharmaceuticalintelligence.com/2018/06/04/june-4-2018-department-of-defense-medical-innovation-and-biodefense-forum-bio-2018-at-boston-convention-exhibition-center/ … via@Pharma_BI -
@TimothyBelski Joint Program Executive Office for Chemical and Biological Defense
@MCS Manufacturing for DoD Infrastructure to manage across Government RFP Process@DoD#MedicalInnovation#BiodefenseForum#BIO2018#MakingBIOHistory@BIOConvention@pharma_BI@AVIVA1950 -
We cover this event in Real Time
@BIOConvention#BIO2018@pharma_BI@AVIVA1950 -
Aviva Lev-Ari Retweeted MassBio
Aviva Lev-Ari added,
-
Aviva Lev-Ari Retweeted JNJ Innovation
Interested
#JNJ Chief Scientific Officer@PaulStoffelsAviva Lev-Ari added,

Original Tweets by @Pharma_BI and by @AVIVA1950 for #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC
June 11, 2018 by 2012pharmaceutical
Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media | Leave a Comment
Follow Blog via Email
Join 9,313 other subscribers-
Recent Posts
- The youngest leader in AI in Health: Tanishq Mathew Abraham, Ph.D. (@iScienceLuvr) January 8, 2026
- 2026 Grok Multimodal Causal Reasoning on Proprietary Cariovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage January 6, 2026
- Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods January 6, 2026
- 2025 Grok 4.1 Causal Reasoning & Multimodal on Identical Proprietary Oncology Corpus: From 673 to 5,312 Novel Biomedical Relationships: A Direct Head-to-Head Comparison with 2021 Static NLP – NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus Transforms Grok into the “Health Go-to Oracle” December 15, 2025
- Marquee Followers 80% Healthcare Persons and Institutions for @AVIVA1950 and @Pharma_BI December 8, 2025
- Exploratory Protocol for Comparison of NLP to LLM on Same Oncology Slice December 8, 2025
- Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP December 8, 2025
- Protected: How will gold and silver medal for Grok be achieved for Domain-aware “AI in Health”: Pharmaceutical/BioPharma, Medical/Diagnosis and Therapeutics, Life Sciences/Genomics and BioMed/Biotech/Medtech December 5, 2025
- Generative AI Providers: Open Source and Closed source, Google’s JAX AI stack versus @xAI and @Grok December 3, 2025
- In Memoriam to Michael R. Bristow, MD, PhD, A Visionary Leader in Heart Failure (HF) Cardiology December 1, 2025
Archives
Categories
Meta


Leave a Reply